Logo

AIMDW

Ainos, Inc.

AIMDW

Ainos, Inc. • NASDAQ
$0.11 ▼ -2.97% (-0.00)
Market Cap $1.88 M
52w High $0.17
52w Low $0.11
Dividend Yield 0%
P/E 0
Volume 2.00K
Outstanding Shares 17.61M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $2.167K ▼ $2.786M ▼ $-2.932M ▲ -135.289K% ▼ $-0.64 ▲ $-1.548M ▲
Q2-2025 $4.663K ▼ $3.749M ▲ $-4.085M ▼ -87.604K% ▼ $-0.99 ▲ $-2.713M ▼
Q1-2025 $106.207K ▲ $3.251M ▼ $-3.286M ▲ -3.094K% ▼ $-207.15 ▼ $-1.928M ▲
Q4-2024 $0 $4.634M ▲ $-4.654M ▼ 0% $-0.49 ▼ $-3.278M ▼
Q3-2024 $0 $3.038M $-3.699M 0% $-0.33 $-2.223M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $1.128M ▼ $22.679M ▼ $12.634M ▲ $10.045M ▼
Q2-2025 $1.223M ▼ $23.922M ▼ $12.479M ▼ $11.443M ▼
Q1-2025 $2.628M ▼ $26.353M ▼ $13.231M ▼ $13.122M ▼
Q4-2024 $3.893M ▼ $28.82M ▼ $13.304M ▼ $15.516M ▼
Q3-2024 $5.157M $31.37M $13.348M $18.022M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-2.932M ▲ $-1.185M ▲ $4.933K ▲ $1.134M ▲ $-94.967K ▲ $-1.195M ▲
Q2-2025 $-4.085M ▼ $-1.35M ▼ $2.542K ▲ $-295.507K ▼ $-1.405M ▼ $-1.343M ▼
Q1-2025 $-3.286M ▲ $-1.225M ▼ $-20.587K ▼ $14.605K ▲ $-1.265M ▼ $-1.258M ▼
Q4-2024 $-4.654M ▼ $-864.231K ▲ $13.285K ▲ $-270K ▲ $-1.264M ▲ $-865.139K ▲
Q3-2024 $-3.699M $-1.475M $-18.785K $-1.482M $-2.857M $-1.485M

Five-Year Company Overview

Income Statement

Income Statement Ainos is still a pure development-stage company: it has essentially no revenue and has been running steady operating losses for several years. The losses are not huge in absolute terms but are persistent, and earnings per share have been negative throughout. This profile is typical of an early biotech / deep-tech firm that is spending on research and platform development long before any commercial sales show up. Profitability will depend entirely on successfully turning its AI Nose and VELDONA pipelines into real products and services over time.

Balance Sheet

Balance Sheet The balance sheet is very small and quite thin. Total assets and shareholder equity are modest, with only a slight cushion to absorb ongoing losses. Reported cash is effectively negligible, and there is now a small layer of debt on the books, which did not exist a few years ago. Overall, the company looks lightly capitalized and financially fragile, meaning its ability to fund operations likely depends on continued access to new financing rather than strength of its current balance sheet.

Cash Flow

Cash Flow Cash generation is weak, which is typical for a company at this stage. Operating cash flow has recently turned negative and free cash flow is also negative, reflecting cash being consumed by day‑to‑day operations and development efforts. There is essentially no spending on heavy equipment or facilities, so almost all cash use is tied to people, research, and commercialization work. Without meaningful incoming cash from customers, the business is likely reliant on raising capital from outside sources to keep funding its plans.

Competitive Edge

Competitive Edge Competitively, Ainos is trying to build a niche in two specialized areas: AI-driven smell detection and low-dose oral interferon therapies. On the positive side, it has a broad patent portfolio, first-mover positioning in “SmellTech-as-a-Service,” and early partnerships in semiconductors, smart factories, healthcare testing, and robotics. Its data-driven “smell language model” could become a defensible asset if adoption grows. On the risk side, it is a very small player facing large, better-funded competitors across both AI hardware/software and biotech. Market acceptance is unproven, and dual focus across two complex fields adds execution risk.

Innovation and R&D

Innovation and R&D Innovation is the clear core of Ainos. The AI Nose platform is an ambitious attempt to make smell a digital input, with applications ranging from industrial monitoring to medical diagnostics and service robots. At the same time, the VELDONA program is a novel take on interferon therapy, aiming for oral, lower-dose treatments with a more tolerable side-effect profile for conditions such as HIV-related oral warts and Sjögren’s syndrome. The company has laid out a multi-year clinical and commercialization roadmap, but progress will hinge on successful trials, regulatory approvals, and the ability to translate prototypes and pilot deployments into scalable, recurring-revenue offerings.

Summary

Overall, Ainos looks like a classic high-risk, innovation-driven micro-cap: scientifically and technologically ambitious, pre-revenue, and financially delicate. Its strengths lie in a differentiated technology stack, an extensive patent base, and early partnerships in both AI sensing and immunotherapy. Its vulnerabilities are the lack of current revenue, ongoing cash burn, a thin balance sheet, and long, uncertain paths to regulatory and commercial success. The story from here will be defined by execution: converting pilots into paying customers on the AI Nose side, advancing VELDONA through clinical milestones, and maintaining sufficient funding to bridge the long gap between today’s development work and any future, sustainable business model.